Research / Stocks / MDXG MDXG Nasdaq CIK 0001376339
MIMEDX GROUP, INC. · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 8-K/A · Aug 11, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT MIMEDX GROUP, INC.'s latest supported as-filed period reports revenue of $64.4M ; gross margin moved 1210 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Debt relative to revenue 90th Own-history percentile · N=10
Method Level · gp.fundamentals.debt_to_revenue
Raw value 26.73% · OPTIONAL
Operating cash generation 0th Own-history percentile · N=12
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -15.56% · OPTIONAL
Revenue growth 0th Own-history percentile · N=8
Method Yoy · gp.fundamentals.revenue
Raw value -34.73% · CORE
Inventory pressure 92th Own-history percentile · N=12
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 32.52% · OPTIONAL
Gross margin 0th Own-history percentile · N=12
Method Level · gp.fundamentals.gross_margin
Raw value 68.96% · CORE
Operating margin 0th Own-history percentile · N=12
Method Level · gp.fundamentals.operating_margin
Raw value -28.69% · CORE
R&D intensity 83th Own-history percentile · N=12
Method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Capital Allocation 4 evidence-backed dimensions Balance Sheet Leverage Inflecting Cash Generation Deteriorating R And D Intensity Stable Sbc Intensity Inflecting [email protected] · 13 historical states · 47% confidenceCompany Direction 8 evidence-backed dimensions Cash Generation Deteriorating Inventory Pressure Inflecting Margin Deteriorating Profitability Deteriorating R And D Intensity Stable [email protected] · 13 historical states · 47% confidenceFinancial Quality 6 evidence-backed dimensions Balance Sheet Leverage Inflecting Cash Generation Deteriorating Inventory Pressure Inflecting Margin Deteriorating Profitability Deteriorating [email protected] · 13 historical states · 48% confidenceGovernance Evidence 4 evidence-backed dimensions Filing Amendments Observed Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 13 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Growth
MDXG -34.7
Peer median 9.2
Peer percentile 5th 76 valid peers · 86% coverage · -2.8 robust σ Inventory Pressure
MDXG 32.5
Peer median 72.6
Peer percentile 14th 79 valid peers · 90% coverage · -1.3 robust σ Profitability
MDXG -28.7
Peer median -5.8
Peer percentile 40th 83 valid peers · 94% coverage · -0.7 robust σ Sbc Intensity
MDXG 1.4
Peer median 5.9
Peer percentile 16th 81 valid peers · 92% coverage · -0.6 robust σ R And D Intensity
MDXG 4.3
Peer median 13.2
Peer percentile 19th 68 valid peers · 77% coverage · -0.6 robust σ Cash Generation
MDXG -15.6
Peer median -6.1
Peer percentile 44th 81 valid peers · 92% coverage · -0.3 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 0
Sales 0
Distinct buyers 0
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001376339-26-000071 11 governed changes · top 7 shown
01
MEDIUM IMPORTANCE Cash 0TH HISTORICAL PCTL · N=2
Cash & equivalents increased 14.3% Cash & equivalents changed +14.3% from the comparable as-filed period.
Why this ranks here · [email protected] $118.9M → $135.8M Comparable → current
02
HIGH IMPORTANCE Debt 50TH HISTORICAL PCTL · N=4
Debt increased 20.0% Debt changed +20.0% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Why this ranks here · [email protected] $1.3M → $1.5M Comparable → current
03
HIGH IMPORTANCE Margin 100TH HISTORICAL PCTL · N=3
Gross margin moved 1210 bp lower Gross margin changed -1210 basis points from the comparable as-filed period.
Why this ranks here · [email protected] 81.05% → 68.96% Comparable → current
04
HIGH IMPORTANCE Margin 100TH HISTORICAL PCTL · N=3
Gross profit decreased 44.5% Gross profit changed -44.5% from the comparable as-filed period.
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 0.62% -19.6% ↓ Capital expenditure $2.0M +216.4% ↑ Cash & equivalents $135.8M +0.0% ↑ Debt $1.5M +0.0% ↑ Free-cash-flow proxy $24.8M +103.8% ↑ Gross margin 68.96% +0.0% ↑ Interest expense $339,000 +294.2% ↑ Interest income $788,000 -11.1% ↓
ACTIVE TRACE Revenue MDXG · as filed with the SEC · reported-date aware
Capex / revenue FY / 2023-12-31 0.62% -19.6% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure FY / 2023-12-31 $2.0M +216.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $135.8M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Debt Q2 / 2026-06-30 $1.5M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy FY / 2023-12-31 $24.8M +103.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2026-06-30 68.96% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense FY / 2016-12-31 $339,000 +294.2% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest income Q2 / 2026-06-30 $788,000 -11.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $20.9M -20.2% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 -$14.8M -36.6% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 -$10.0M -633.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 -28.69% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
8-K/A Aug 11, 2026 Period Jul 29, 2026 0001376339-26-000082SEC ↗ 8-K Jul 29, 2026 Period Jul 29, 2026 0001376339-26-000074SEC ↗ 10-Q Jul 29, 2026 Period Jun 30, 2026 0001376339-26-000071SEC ↗ 8-K Jul 29, 2026 Period Jul 29, 2026 0001376339-26-000070SEC ↗ 4 Jul 7, 2026 Period Jul 2, 2026 0001376339-26-000057SEC ↗ 4 Jun 25, 2026 Period Jun 24, 2026 0001376339-26-000054SEC ↗ 8-K Jun 16, 2026 Period Jun 10, 2026 0001376339-26-000052SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗